title: Mortality in inflammatory bowel disease in the Netherlands 1991-2002: results of a population-based study: the IBD South-Limburg cohort.
abstract: BACKGROUND
  The aim was to evaluate overall and disease-specific mortality in a population-based inflammatory bowel disease (IBD) cohort in the Netherlands, as well as risk factors for mortality.
  
  
  METHODS
  IBD patients diagnosed between 1 January 1991 and 1 January 2003 were included. Standardized mortality ratios (SMRs) were calculated overall and with regard to causes of death, gender, as well as age, phenotype, smoking status at diagnosis, and medication use.
  
  
  RESULTS
  At the censoring date, 72 out of 1187 patients had died (21 Crohn's disease [CD], 47 ulcerative colitis [UC], and 4 indeterminate colitis [IC] patients). The SMR (95% confidence interval [CI]) was 1.1 (0.7-1.6) for CD, 0.9 (0.7-1.2) for UC and 0.7 (0.2-1.7) for IC. Disease-specific mortality risk was significantly increased for gastrointestinal (GI) causes of death both in CD (SMR 7.5, 95% CI: 2.8-16.4) and UC (SMR 3.4, 95% CI: 1.4-7.0); in CD patients, especially in patients <40 years of age at diagnosis. For UC, an increased SMR was noted in female patients and in patients <19 years and >80 years at diagnosis. In contrast, UC patients had a decreased mortality risk from cancer (SMR 0.5, 95% CI; 0.2-0.9).
  
  
  CONCLUSIONS
  In this population-based IBD study, mortality in CD, UC, and IC was comparable to the background population. The increased mortality risk for GI causes might reflect complicated disease course, with young and elderly patients at diagnosis needing intensive follow-up. Caution in interpreting the finding on mortality risk from cancer is needed as follow-up was probably to short to observe IBD-related cancers.
authors.affiliation: Department of Gastroenterology and Hepatology, Maastricht University Medical Center, the Netherlands. m.camps@orbisconcern.nl
authors.forename: Mariëlle
authors.initials: M
authors.lastname: Romberg-Camps
authors.forename: Edith
authors.initials: E
authors.lastname: Kuiper
authors.forename: Leo
authors.initials: L
authors.lastname: Schouten
authors.forename: Arnold
authors.initials: A
authors.lastname: Kester
authors.forename: Martine
authors.initials: M
authors.lastname: Hesselink-van de Kruijs
authors.forename: Charles
authors.initials: C
authors.lastname: Limonard
authors.forename: Rens
authors.initials: R
authors.lastname: Bos
authors.forename: Jelle
authors.initials: J
authors.lastname: Goedhard
authors.forename: Wim
authors.initials: W
authors.lastname: Hameeteman
authors.forename: Frank
authors.initials: F
authors.lastname: Wolters
authors.forename: Maurice
authors.initials: M
authors.lastname: Russel
authors.forename: Reinhold
authors.initials: R
authors.lastname: Stockbrügger
authors.forename: Pieter
authors.initials: P
authors.lastname: Dagnelie
mesh_terms: D000328:Adult; D000368:Aged; D002423:Cause of Death; D015331:Cohort Studies; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000401:mortality; D009426:Netherlands / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D012907:Smoking / Q000453:epidemiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005765:Gastrointestinal Agents